471-53-4

  • Product Name:Enoxolone
  • Molecular Formula:C30H46O4
  • Purity:99%
  • Molecular Weight:
Inquiry

Product Details

Appearance:white or greyish-white crystalline powder

471-53-4 Properties

  • Molecular Formula:C30H46O4
  • Molecular Weight:470.693
  • Appearance/Colour:white or greyish-white crystalline powder 
  • Vapor Pressure:2.71E-16mmHg at 25°C 
  • Melting Point:292-295 °C(lit.) 
  • Refractive Index:162 ° (C=1, MeOH) 
  • Boiling Point:588.3 °C at 760 mmHg 
  • PKA:pKa 5.56±0.1 (Uncertain) 
  • Flash Point:323.7 °C 
  • PSA:74.60000 
  • Density:1.14 g/cm3 
  • LogP:6.41260 

471-53-4 Usage

Description

Extracting from liquorice (Glycyrrhiza uralensis Fisch, Gan Cao), glycyrrhetic acid also can be detected in other plants, such as Abrus cantoniensis Hance and Herba Abri fruticulosi. As one of traditional Chinese medicines, liquorice has been applied clinically for a long period. Due to its extensive usage, it plays an extremely important role in traditional Chinese medicine formula mainly as “guide” drug. As is recorded in Shen Nong’s Herbal Classic and later in pharmaceutical monographs, liquorice is able to strengthen bones and muscles and enhance metabolism and detoxification. Also, abnormal symptoms of the body and wound can be improved. Glycyrrhetic acid, the most important and potent ingredient of liquorice, has been recorded in Pharmacopoeia of the People’s Republic of China.

Description

18β-Glycyrrhetinic acid is a major metabolite of glycyrrhizin , one of the main constituents of licorice. Both 18β-glycyrrhetinic acid and glycyrrhizin have been shown to exhibit anti-ulcerative, anti-inflammatory, and immunomodulatory properties. 18β-Glycyrrhetinic acid is an inhibitor of the complement pathway (IC50 = 35 μM). At 100 mg/kg/day, 18β-glycyrrhetinic acid is protective against diabetes complications by reducing lipid peroxidation and increasing antioxidant activity in diabetic rats. 18β-Glycyrrhetinic acid inhibits mammalian DNA polymerases α, γ, κ, and λ with IC50 values of 16.1, 19.3, 15.8, and 13.7 μM, respectively. At 100-200 μM, 18β-glycyrrhetinic acid suppresses LPS-induced TNF-α production and NF-κB activation in mouse macrophages.

Chemical Properties

white or greyish-white crystalline powder

Physical properties

Solubility: insoluble in water; it exists in crystal with methanol and chloroform. Melting point: the compound melts at 292–295?°C. Specific optical rotation: under the condition of 20?°C, 589.3?nm, and 1?dm, polarized light rotates at 68° when it passes through the chloroform with a concentration of 64? mol/L.? Both 18α-glycyrrhetic acid and 18β-glycyrrhetic acid are chiral isomers of glycyrrhetic acid.

History

Glycyrrhetic acid originates from hydrolysis of glycyrrhizin, which has a therapeutic effect on disease. Dating back to the 1930s, the chemical structure of glycyrrhetic acid was demonstrated . Subsequently, the discovery of antiulcer activity promotes following research . The ramification of glycyrrhetic acid, carbenoxolone sodium, has a therapeutic effect on ulcer. In 2010, followed by the approval of raw materials, batches of tablets and capsules were approved in 2009, respectively. In foreign countries, 18β-glycyrrhetic acid was studied for anti-inflammatory effect on arthritis, rheumatoid disease, and periodontitis in BioNetWorks. The company applied for the patent of 18β-glycyrrhetic acid in 1999. Also, after joining the leading worldwide market in 2006, phase III clinical trials would be carried out in 2007. However, the progress was hindered in 2008. To detecting more indications, its carbenoxolone sodium was studied by other three companies: after conducting phase III clinical trials in the UK, the project of RB intending to improve nonspecific inflammatory bowel disease was given up in 1992. York Pharma expected to make progress in psoriasis with gel or cream; however, the project has been in a standstill after phase II clinical trials was conducted from 2005 to 2009. Canada pharmaceutical company, Oxalys Pharmaceuticals, research it for treating Huntington’s disease, and it was included in the orphan drug list by the USA in 2014. Till now, phase I clinical trials are still continuing.

Uses

The product may be used as a starting material to prepare 18β-glycyrrhetinic acid derivatives, which show anti-inflammatory and antioxidant properties.

Uses

An anti-inflammatory (topical).

Uses

antitussive, antiinflammatory, antibacterial

Uses

The aglycone of the triterpenoid Glyccyrrhizic acid.

Uses

glycyrrhetinic acid is anti-irritant, anti-allergenic, anti-inflammatory, skin-lightening, and smoothing properties are attributed to this ingredient, which is also a carrier. It is the organic compound derived from glycyrrhizic acid or shredded licorice roots.

Definition

ChEBI: A pentacyclic triterpenoid that is olean-12-ene substituted by a hydroxy group at position 3, an oxo group at position 11 and a carboxy group at position 30.

Indications

Treatment of Addison’s disease, deoxycorticosterone

General Description

18β-Glycyrrhetinic acid is a pentacyclic triterpenoid found in the Glycyrrhiza glabra L.(liquorice) roots. It is the key metabolite of glycyrrhizin and glycyrrhizic acid.

Pharmacology

Thirty percent of glycyrrhetinic acid can be effectively used by the body; both 18α-glycyrrhetic acid and 18β-glycyrrhetic acid reduce by half in 2.24 h and 11.5 h separately. CYP3A promotes metabolism with hydroxyl added to 22α and 24α .There are lots of pharmacological activities : it plays an anti-inflammatory role by inhibiting the activity of phospholipase A2 and lipoxygenase to reduce mediators of inflammation; the compound promotes antiulcer activity through the production of more PGE2 and secretion of gastric mucus; it also provokes proliferation of gastric cell to protect the mucosa from ulceration. The complex which consists of glycyrrhetinic acid and carotenoid plays antioxidation by scavenging free radical. Glycyrrhetinic acid inhibits the replication of viral DNA to achieve an antiviral effect at the concentration of 4×10?5 mol/L; it also inhibits proliferation of tumor cell and promotes apoptosis and differentiation. The decreasing ability of invasion exerts an antitumor effect. Glycyrrhetinic acid is considered to have extensive antiarrhythmic effects through inhibition of L-type calcium channel. In addition, glycyrrhetinic acid functions as an anticholinesterase (1.7×10?5 mol/L), anticoagulant, and antitetanus toxin; it also improves inner ear hearing (100 mg/kg, intramuscular injection) and improves absorption of insulin.

Anticancer Research

Glycyrrhetinic acid in combinationwith etoposide inhibits thetopoisomerase 2α and inducesapoptosisCai et al.(2017)

Anticancer Research

It was reported that GA at noncytotoxic concentrationshowed synergistic effect in combination with anticancer drug, etoposide (VP-16).Specifically, GA enhanced cytotoxicity through regulating topoisomerase II-αtargeted by etoposide. Also, GA sensitized the cells to etoposide through elevatingtopoisomerase II-α with a 2.4-fold rate at 12 h time point. From 12 to 48 h, GAhalved the expression of topoisomerase II-α and stimulated apoptosis, whichexhibited its antineoplastic effect. They reported that GA was more potentiallyeliminating the TNBC cells when compared with Glycyrrhizin Acid (Cai et al. 2017).

Clinical Use

Glycyrrhetic acid has not been applied in clinical treatment till now. Meanwhile, the ramification has come into the market for the property of antiulcer. However, with large doses and long-term usage, the drug gives rise to hypertension, sodium retention, and hypokalemia. When renin-angiotensin-aldosterone system fails to function properly, liquorice-induced pseudoaldosteronism threatens human health .

InChI:InChI=1/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h16,19,21-23,32H,8-15,17H2,1-7H3,(H,33,34)/t19-,21?,22-,23?,26+,27-,28-,29+,30+/m0/s1

471-53-4 Relevant articles

Glycyrrhiza glabra extract and quercetin reverses cisplatin resistance in triple-negative MDA-MB-468 breast cancer cells via inhibition of cytochrome P450 1B1 enzyme

Sharma, Rajni,Gatchie, Linda,Williams, Ibidapo S.,Jain, Shreyans K.,Vishwakarma, Ram A.,Chaudhuri, Bhabatosh,Bharate, Sandip B.

, p. 5400 - 5403 (2017)

The development of multi-drug resistance to existing anticancer drugs is one of the major challenges in cancer treatment. The over-expression of cytochrome P450 1B1 enzyme has been reported to cause resistance to cisplatin. With an objective to discover cisplatin-resistance reversal agents, herein, we report the evaluation of Glycyrrhiza glabra (licorice) extracts and its twelve chemical constituents for inhibition of CYP1B1 (and CYP1A1) enzyme in Sacchrosomes and live human cells. The hydroalcoholic extract showed potent inhibition of CYP1B1 in both Sacchrosomes as well as in live cells with IC50 values of 21 and 16 μg/mL, respectively. Amongst the total of 12 constituents tested, quercetin and glabrol showed inhibition of CYP1B1 in live cell assay with IC50 values of 2.2 and 15 μM, respectively. Both these natural products were found to be selective inhibitors of CYP1B1, and does not inhibit CYP2 and CYP3 family of enzymes (IC50 > 20 μM). The hydroalcoholic extract of G. glabra and quercetin (4) showed complete reversal of cisplatin resistance in CYP1B1 overexpressing triple negative MDA-MB-468 breast cancer cells. The selective inhibition of CYP1B1 by quercetin and glabrol over CYP2 and CYP3 family of enzymes was studied by molecular modeling studies.

STUDY OF KINETICS OF ENZYMATIC HYDROLYSIS OF AMMONIUM GLYCYRRHIZATE

Murav'ev, I. A.,Savchenko, L. N.

, p. 645 - 647 (1985)

-

Oleanane-type triterpene glucuronides from the roots of Glycyrrhiza uralensis Fischer

Zheng, Yun-Feng,Qi, Lian-Wen,Cui, Xiao-Bing,Peng, Guo-Ping,Peng, Yong-Bo,Ren, Mei-Ting,Cheng, Xiao-Lan,Li, Ping

, p. 1457 - 1463 (2010)

Investigation of characteristic constituents of the roots of Glycyrrhiza uralensis Fischer led to isolation of four new triterpene glucuronides, namely uralsaponins CF (1-4), an artificial product, namely the methyl ester of glycyrrhizin (5), as well as six known triterpene glucuronides (6-11). These new compounds were identified by 1D and 2DNMR spectroscopic analysis. The cytotoxicity of the selected compounds and their aglycones were evaluated against HeLa and MCF-7 cancer cell lines, and the preliminary structure-activity relationship was also elucidated.

3-(2,6-Dichloro-benzyloxy)-11-oxo-olean-12-ene-29-oic acid, a semisynthetic derivative of glycyrrhetic acid: Synthesis, antiproliferative, apoptotic and anti-angiogenesis activity

Sharma, Rajni,Guru, Santosh K.,Jain, Shreyans K.,Pathania, Anup Singh,Vishwakarma, Ram A.,Bhushan, Shashi,Bharate, Sandip B.

, p. 564 - 575 (2015)

Glycyrrhetic acid (2, 3β-hydroxyl-11-oxo-olean-12-ene-29-oic acid), a pentacyclic triterpenoid isolated from Glycyrrhiza glabra, is known to possess a wide range of biological activities. Herein, we report the synthesis and antiproliferative activity of 3-O-ether derivatives of glycyrrhetic acid. The cytotoxicity of the prepared derivatives was investigated in three cancer cell lines, including human pancreatic (MIAPaCa-2), prostate (PC-3) and human hepatocellular liver carcinoma (HepG-2). Amongst the tested compounds, the 2,6-dichlorobenzyl 5b and 2,4-dichlorobenzyl derivative 5r displayed significant cytotoxicity in PC-3 cells with IC50 values of 6 and 18 μM, respectively. The dichlorobenzyl derivative 5b also displayed cytotoxicity in MIAPaCa-2 (IC50: 7 μM) and HepG-2 cells (IC50: 19 μM). Further, compound 5b was investigated for apoptosis-induction by cell cycle analysis, nuclear morphological changes and mitochondrial membrane potential loss in PC-3 cells. Compound 5b led to an increase in the sub-G1 population in PC-3 cells, which is indicative of its apoptotic properties. Interestingly, compound 5b also arrested the S-phase of the cell cycle. The nuclear morphology of PC-3 cells after treatment with compound 5b was also investigated which confirmed the formation of apoptotic bodies. Compound 5b induced apoptosis through both intrinsic and extrinsic apoptotic pathways in PC-3 cells, which was confirmed by mitochondrial membrane potential loss, inhibition of pro-caspase-3, 8 and 9 and cleavage of PARP-1. Furthermore, there was a significant decrease in the Bcl-2/Bax ratio induced by compound 5b in PC-3 cells. Interestingly, compound 5b also inhibited the VEGF-induced PC-3 cell migration and decreased the wound closure percentage from 100 to 12% at 30 μM. Similarly, compound 5b inhibited the angiogenesis-dependent cell migration in HUVEC cells and decreased wound closure from 100 to 20% at 30 μM, indicating its anti-angiogenic activity. This journal is

Self-assembly of a renewable nano-sized triterpenoid 18β-glycyrrhetinic acid

Bag, Braja Gopal,Majumdar, Rakhi

, p. 8623 - 8626 (2012)

The nano-sized triterpenoid 18β-glycyrrhetinic acid extractable from Glycyrrhiza glabra self assembled in different liquids affording mostly nano to microsized spherical and flower like objects consisting of fibrillar networks yielding thermoreversible gels. The self-assemblies have been utilized for the templated growth of CdS nanoparticles.

Oestrogenic activity of enoxolone in rodents

Dekanski,Gottfried,MacDonald

, p. 62 - 62 (1979)

-

Application of bacterial directed enzyme prodrug therapy as a targeted chemotherapy approach in a mouse model of breast cancer

Bahrami, Ahmad Reza,Hosseini-Giv, Niloufar,Matin, Maryam M.

, (2021/08/03)

Cancer is the second leading cause of death in the world. Some of the usual cancer treatments include surgery, chemotherapy, and radiotherapy. However, due to low efficacy and side effects of these treatments, novel targeted therapeutic methods are needed. One of the common drawbacks of cancer chemotherapy is off-target toxicity. In order to overcome this problem, many investigations have been conducted. One of the new targeted therapy methods known as bacterial directed enzyme-prodrug therapy (BDEPT) employs bacteria as enzyme carriers to convert a pro-drug to a drug specifically within the tumor site. In the present study, we used Escherichia coli DH5α carrying luxCDABE gene cluster and overexpressing β-glucuronidase for luminescent emission and enzyme expression, respectively. Enzyme expression can lead to the conversion of glycyrrhizic acid as a prodrug to glycyrrhetinic acid, a potent anti-cancer agent. DH5α-lux/βG was characterized and its stability was also evaluated. Bacteria colonization in the tumor site was measured by tissue homogenate preparation and colony counting method. Histopathological studies on the liver, spleen, and tumor were also conducted. According to the results, co-treatment of 4T1, a highly metastatic mouse breast cancer cell line, with GL and DH5α-lux/βG could significantly decrease the IC50 values. Moreover, increased number of bacteria could lead to a dramatic drop in IC50 value. Specific colonization of DH5α-lux/βG was observed in the tumor site compared with other tissues (p 0.0001). Moreover, the biocompatibility evaluation proved that DH5α-lux/βG had no adverse effects on normal tissues. Furthermore, concurrent usage of GL and bacteria in the treatment of induced 4T1 tumors in BALB/c mice significantly delayed tumor growth (p0.001) during 16 days of investigation. Based on these findings, BDEPT might be useful for targeted breast cancer therapy, although further investigations are required to confirm this.

2D- and 3D-QSAR modelling, molecular docking and in vitro evaluation studies on 18β-glycyrrhetinic acid derivatives against triple-negative breast cancer cell line

Shukla, Aparna,Tyagi, Rekha,Meena, Sanjeev,Datta, Dipak,Srivastava, Santosh Kumar,Khan, Feroz

, p. 168 - 185 (2019/03/07)

Triple-negative breast cancers (TNBCs) are one of the most aggressive and complex forms of cancers in women. TNBCs are commonly known for their complex heterogeneity and poor prognosis. The present work aimed to develop a predictive 2D and 3D quantitative structure–activity relationship (QSAR) models against metastatic TNBC cell line. The 2D-QSAR was based on multiple linear regression analysis and validated by Leave-One-Out (LOO) and external test set prediction approach. QSAR model presented regression coefficient values for training set (r2), LOO-based internal regression (q2) and external test set regression (pred_r2) which are 0.84, 0.82 and 0.75, respectively. Five properties, Epsilon4 (electronegativity), ChiV3cluster (valence molecular connectivity index), chi3chain (retention index for three-membered ring), TNN5 (nitrogen atoms separated through 5 bond distance) and nitrogen counts, were identified as important structural features responsible for anticancer activity of MDA-MB-231 inhibitors. Five novel derivatives of glycyrrhetinic acid (GA) named GA-1, GA-2, GA-3, GA-4 and GA-5 were semi-synthesised and screened through the QSAR model. Further, in vitro activities of the derivatives were analysed against human TNBC cell line, MDA-MB-231. The result showed that GA-1 exhibits improved cytotoxic activity to that of parent compound (GA). Further, atomic property field (APF)-based 3D-QSAR and scoring recognise C-30 carboxylic group of GA-1 as major influential factor for its anticancer activity. The significance of C-30 carboxylic group in GA derivatives was also confirmed by molecular docking study against cancer target glyoxalase-I. Finally, the oral bioavailability and toxicity of GA-1 were assessed by computational ADMET studies. Communicated by Ramaswamy H. Sarma.

Derivatization, molecular docking and in vitro acetylcholinesterase inhibitory activity of glycyrrhizin as a selective anti-Alzheimer agent

Abdel Bar, Fatma M.,Elimam, Diaaeldin M.,Mira, Amira S.,El-Senduny, Fardous F.,Badria, Farid A.

supporting information, p. 2591 - 2599 (2018/04/20)

Acetylcholinesterase inhibitors (AChE-Is) increase both level and duration of action of acetylcholine (ACh); thus, alleviate symptoms of Alzheimer’s disease (AD). Glycyrrhizin, is the main active compound in liquorice root. Its aglycone, glycyrrhetinic acid, has shown several beneficial pharmacological activities. This study reports the synthesis and screening of a series of glycyrrhetinic acid analogs as AChE-Is. Fourteen derivatives were prepared, of which five derivatives are recorded as new viz., 3-phenyl-carbamoyl-18β-glycyrrhetinic acid (J9), 3-acetyl-18β-glycyrrhetinic-30-anilinamide (J10), 3-acetyl-18β-glycyrrhetinic-30-ethanolamide (J11), 3-acetyl-18β-glycyrrhetinic-30-n-butylamide (J12) and 18β-glycyrrhetinic acid-30-prenyl ester (J14), in addition to nine known derivatives (J1-J8 & J13). Compounds J12, J11, J0 and J3 showed remarkable AChE-I activity with IC50 values of 3.43, 5.39, 6.27 and 8.68?μM, respectively. These results are in full agreement with the docking study. The active compounds were non-cytotoxic to normal cells (WI-38).

Direct Carbon Isotope Exchange through Decarboxylative Carboxylation

Kingston, Cian,Wallace, Michael A.,Allentoff, Alban J.,Degruyter, Justine N.,Chen, Jason S.,Gong, Sharon X.,Bonacorsi, Samuel,Baran, Phil S.

supporting information, p. 774 - 779 (2019/01/14)

A two-step degradation-reconstruction approach to the carbon-14 radiolabeling of alkyl carboxylic acids is presented. Simple activation via redox-active ester formation was followed by nickel-mediated decarboxylative carboxylation to afford a range of complex compounds with ample isotopic incorporations for drug metabolism and pharmacokinetic studies. The practicality and operational simplicity of the protocol were demonstrated by its use in an industrial carbon-14 radiolabeling setting.

471-53-4 Process route

glycyrrizhin
83896-44-0,103000-77-7,119479-05-9,142394-43-2,1405-86-3

glycyrrizhin

D-glucuronic acid
6556-12-3,489-91-8,528-16-5,552-12-5,577-46-8,643-33-4,2240-07-5,6294-16-2,10133-02-5,18402-78-3,18968-14-4,21179-08-8,23018-83-9,33599-45-0,33599-46-1,46171-67-9,46171-69-1,46172-26-3,70021-34-0,71031-08-8,104195-06-4,106499-29-0,124817-72-7

D-glucuronic acid

enoxolone
471-53-4

enoxolone

11-deoxyglycyrrhetinic acid
6894-46-8,14796-53-3,17956-00-2,76035-62-6,564-16-9

11-deoxyglycyrrhetinic acid

Conditions
Conditions Yield
With hydrogenchloride; In water; at 100 ℃; for 8h;
69.9%
1.1%
glycyrrizhin
83896-44-0,103000-77-7,119479-05-9,142394-43-2,1405-86-3

glycyrrizhin

D-glucuronic acid
6556-12-3,489-91-8,528-16-5,552-12-5,577-46-8,643-33-4,2240-07-5,6294-16-2,10133-02-5,18402-78-3,18968-14-4,21179-08-8,23018-83-9,33599-45-0,33599-46-1,46171-67-9,46171-69-1,46172-26-3,70021-34-0,71031-08-8,104195-06-4,106499-29-0,124817-72-7

D-glucuronic acid

enoxolone
471-53-4

enoxolone

Conditions
Conditions Yield
With β-glucuronidase; In acetate buffer; at 37 ℃; for 144h; pH=5.2; Enzymatic reaction;
45.9%

471-53-4 Upstream products

  • 10379-73-4
    10379-73-4

    acetoxolone

  • 67-56-1
    67-56-1

    methanol

  • 121709-66-8
    121709-66-8

    apioglycyrrhizin

  • 121687-83-0
    121687-83-0

    araboglycyrrhizin

471-53-4 Downstream products

  • 486-34-0
    486-34-0

    1,2,7-trimethylnaphthalene

  • 1449-05-4
    1449-05-4

    18-α-glycyrrhetinic acid

  • 1477-44-7
    1477-44-7

    methyl glycyrrhetinate

  • 6894-46-8
    6894-46-8

    11-deoxyglycyrrhetinic acid